Dual b-lactam-fluoroquinolone compounds: a novel approach to antibacterial treatment

Author: Bryskier A.  

Publisher: Informa Healthcare

ISSN: 1354-3784

Source: Expert Opinion on Investigational Drugs, Vol.6, Iss.10, 1997-10, pp. : 1479-1500

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Codrugs comprise a b-lactam-fluoroquinolone antibacterial hybrid. These new agents have been developed with the aim of enhancing the antibacterial spectrum of current therapies, overcoming intrinsic and acquired resistance, and diminishing severe side-effects. A few compounds, including Ro 23-9424, have entered Phase I clinical trials. Furthermore, a series of oral codrugs have been synthesised, although clear oral bioavailability has not yet been demonstrated. New drugs are urgently needed to treat Gram-positive resistant bacteria.